Evidence map›Paper›PMID 33747564›Full record

ArticleMultiple sclerosis international2021

A Prospective Multicenter Study for Assessing MusiQoL Validity among Arabic-Speaking MS Patients Treated with Subcutaneous Interferon

Mohammed Al Jumah, Suleiman Kojan, Raed Alroughani, Edward Cupler, Saeed Bohlega, Abdulkader Daif, Mousa Al Mujalli, Talal Al Harbi, Mohamed El Tamawy, Samia Ashour and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Multiple sclerosis international, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Observational
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Mohammed Al JumahKing Fahad Medical City, MOH, As Sulimaniyah, Riyadh 12231, Saudi Arabia.ORCID https://orcid.org/0000-0002-9820-9579
Suleiman KojanKing Abdullah International Medical Research Center, King Saud bin Abdulaziz University for Health Sciences, King Abdulaziz Medical City, National Guard Health Affairs, Riyadh 11481, Saudi Arabia.
Raed AlroughaniDivision of Neurology, Department of Medicine, Amiri Hospital, Gulf Road, Bin Misbah St, Sharq, Kuwait.
Edward CuplerDepartment of Neuroscience, King Faisal Specialist Hospital and Research Centre, Al Rawdah Street, Jeddah, Saudi Arabia.
Saeed BohlegaNeurology Department, King Faisal Specialist Hospital, Zahrawi St, Riyadh 12713, Saudi Arabia.
Abdulkader DaifNeurology Department, King Khalid University Hospital, Riyadh 12372 6864, Saudi Arabia.
Mousa Al MujalliNeurology Department, Herrah General Hospital, Makkah 20993, Saudi Arabia.
Talal Al HarbiNeurology Department, King Fahad Specialist Hospital, Ammar Bin Thabit St, Al Merikbat Neighborhood, Dammam 32253, Saudi Arabia.
Mohamed El TamawyNeurology Department, Cairo University Hospital, Old Cairo, Cairo Governorate, Egypt.
Samia AshourNeurology Department, Faculty of Medicine, Ain Shams University, El-Khalyfa El-Mamoun St, El-Abaseya, Egypt.
Chokri MhiriHabib Bourguiba Hospital, Rue Al Firdaws, 3029 Sfax, Tunisia.
Riadh GouiderRazi Hospital, 1st Street Ovanges, 2010 Manouba, Tunisia.
Ayah JawharyKing Abdullah International Medical Research Center, King Saud bin Abdulaziz University for Health Sciences, King Abdulaziz Medical City, National Guard Health Affairs, Riyadh 11481, Saudi Arabia.
Ahmed El BoghdadyMerck Serono, Tahaliyah St, 502 Jameel Square, Jeddah, Saudi Arabia, An Affiliate of Merck KGaA, Darmstadt, Germany.
Mohamed HusseinKing Abdullah International Medical Research Center, King Saud bin Abdulaziz University for Health Sciences, King Abdulaziz Medical City, National Guard Health Affairs, Riyadh 11481, Saudi Arabia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Few studies examine health-related quality of life (HRQoL) in Arabic-speaking multiple sclerosis (MS) patients. However, HRQoL tools such as the Short Form-36 QoL instrument (SF-36) and the Multiple Sclerosis International QoL (MusiQoL) questionnaire have been validated in other languages. The primary objective of this study was to prospectively assess HRQoL using the MusiQoL questionnaire among Arabic-speaking MS patients treated with subcutaneous interferon (sc IFN

Identifiers

PMID33747564
PMCPMC7943271

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.